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Abstract 
 
Background: Restless leg syndrome (RLS) is defined as an uncomfortable feeling in the limbs which is promi-
nently sensed in legs. Dopamine system involvement is considered as the base of RLS’s etiology. Because of 
safety, anti-oxidant and dopaminergic promoting action of selenium, this study aims to investigate the effect of 
selenium on restless leg syndrome treatment. 
 
Methods: Sixty patients with primary RLS were enrolled in this clinical trial (Irct2011103015943n1). It was based 
on 3 periods of drug prescription with one month wash out period. As placebo, 50 and 200 µg of selenium were 
administered in each separated month. The diagnosis was based on criteria published by IRLSG (International 
RLS Study Group). The questionnaire included 10 questions while each question’s rating was between 0 and 4. 
Points between 1 and 10 were considered mild, 11 to 20 as moderate, 21 to 30 as severe and 31 to 40 as very 
severe. After end of each month of drug consumption, questionnaires were completed and each subject was 
asked to report the severity of disease and side effects of the drugs. At least 10 declines in scale were consid-
ered as appropriate responses. 
 
Results: Improvement (decline IRLS score >10) was significantly higher in selenium (50 and 200 µg) than pla-
cebo group. 
 
Conclusion: Selenium prescription in daily recommended dose of 50 µg instead of a dopamine agonist would be 
an alternative treatment in improvement of RLS symptoms. 
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Introduction 
 
Restless leg syndrome (RLS) is defined as an uncom-
fortable feeling in the limbs which is prominently 
sensed in legs and rarely in arms.
1 This disturbing 
feeling leads to restless and forces patient to move the 
limbs which is pathognomonic manifestation of RLS. 
This movement leads to complete but temporary 
relief of symptoms. These symptoms occur only in 
rest and are intensified in evening or night time.
1 The 
prevalence of disease was shown to be 5-10%.
1-3 and 
the prevalence increased by aging.
3 In addition to 
sensory symptoms, motor symptoms such as periodic 
limb movement syndrome, myoclonic Jerking exist 
during the patient's sleep.
1,2 Since these symptoms 
may occur during sleep, most of patients have some 
difficulty in start of sleeping or during sleep which 
may lead to fatigue and excessive daily sleepiness. 
Thus RLS is one of the most important causes of in-
somnia and sleepiness during the day.
4 The etiology 
of RLS is not precisely defined yet but it may be pri-
mary (idiopathic) or secondary. Primary cases are 
commonly genetical and are presented as autosomal 
dominant patterns.
5-8 Secondary types are associated 
with diseases such as iron deficiency anemia, folic 
acid deficiency, renal failure and physiological condi-
tions such as pregnancy.
1,9  Also some case reports 
showed an association between RLS and diabetes 
melitus, rhematoid arthritis and amyloidosis.
1,9 
RLS may be induced secondary to drug consump-
tion such as lithium, three cyclic antidepressants, do-
pamine blockers like metoclopramide and phenothia-
zines.
1-3 Some facts such as response to dopaminergic 
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drugs, drug induced RLS like anti-dopaminergics, 
hypoactivity of dopamine system, decreased connec-
tion to dopamine receptors in basal ganglia
4,10,11 im-
plicate this hypothesis that dopamine system in-
volvement may be the main cause. The diagnosis is 
clinical and the most important role in diagnosis is the 
history of uncomfortable feeling in limbs which oc-
curs only at rest and is aggravated in evening and 
night time and is relieved by limb movement.
1,11 Di-
agnostic criteria published by IRLSG (International 
RLS Study Group) were shown in Table 1.
12 Some 
laboratory studies are necessary for diagnosis com-
pletion including renal function test, cell blood count, 
serum iron, ferritin and folic acid levels, EMG-NCV 
and polysomnography for periodic limb movement 
syndrome(PLMS).
1,4,11 In recent years, questionnaire 
for diagnosis and severity determination of RLS has 
been established by Benoy and Kohnen which is a 
gold standard for the diagnosis and severity determi-
nation. The questionnaire includes 10 questions while 
each question is rated between 0 and 4. Points be-
tween 1 and 10 are considered mild, 11 to 20 as mod-
erate, 21 to 30 as severe and 31 to 40 cas very se-
vere.
4,9,13,14 Differential diagnosis are peripheral neu-
ron diseases such as painful peripheral neuropathy, 
vascular diseases such as peripheral vascular diseases, 
varicose and erythromelalgia, movement disorders 
such as akathisia, extra pyramidal tremor, etc.
1,4,11 
RLS treatment is based on two approaches including 
pharmacologic and non-pharmacologic. Non-
pharmacologic approaches include treatment of the 
underlying causes like iron supplementary consump-
tion in iron deficient patients, kidney transplantation 
in uremic patients, drug induced RLS withdrawal, 
prevention of stimulating subject consumptions such 
nicotine, alcohol and caffeine. Also sleep hygiene has 
an important role in reduction of the disturbances.
1,4,9 
Pharmacologic approaches include dopaminergic 
drugs such as levodopa,
9,15 pramipexole,
9 ropin-
rinol
2,9,15 and pergolide,
2,15 benzodiazepines,
15 opioids 
such as propoxyphen subsulicylate,
2 antiepileptics 
such as gabapentin,
2 iron and folic acid.
15 
Selenium was discovered by Brezilus in 1814.
16 In 
1957, Foltz and Schwarz implicated that selenium is a 
rare essential element existing in dietary regimen and 
has a preventive role for the diseases.
17 Body selenium 
concentration is related to its soil concentration.
18,19 
This concentration in some countries like United States 
of America is high and is low in China.
20-22 In 1973, 
Rotrack and colleagues demonstrated the anti-
oxidative role of selenium.
15 Role of selenium as anti-
oxidant and anti-inflammatory in reverse striatal do-
pamine depletion
23 and decrease in thyrosine hydrox-
ylase activity were shown.
24,25 Selenium is adminis-
tered by two routes in selenium deficient patients in-
cluding enteral and parenteral. Also it is prescribed as 
supplementary diet in pregnant or breast-feeding 
mothers.
26 In advised doses, no side effects were re-
ported. Even no intoxicated cases with doses up to 400 
mg for prostate cancer prevention were shown.
27-30 Be-
cause of its safety, and anti-oxidative and dopaminer-
gic promoting actions and dopaminergic agonist side 
effects, we were encouraged to establish this study to 
determine the effect of selenium in RLS treatment.  
Table1: Diagnostic criteria for RLS 
Essential criteria 
1. An urge to move the legs usually accompanied by uncomfortable and unpleasant sensation in the legs. 
2. The urge to move or unpleasant sensations to be begun or worsen during periods of rest or inactivity such as 
lying or sitting. 
3. The urge to move or unpleasant sensations to be partially or totally relieved by movement such as walking or 
stretching at least as long as the activity continues. 
4. The urge to move or unpleasant sensation to be worsen in the evening or night than during the day or only to 
be occurred in the evening or night. 
Supportive features 
1. Positive family history 
2. Positive response to dopaminergic therapy  
3. Periodic limbs movements   
Associated features 
1. Natural clinical course  
2. Sleep disturbance 
3. Medical evaluation/physical examination. 
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Materials and Methods  
 
In our study, which began in June 2010 and lasted 
until November 2010, initially 68 patients were en-
rolled with diagnosis of primary RLS based on 
IRLSSG. The trial was an experimental study and was 
registered in IRCT (Code: Irct2011103015943n1). All 
patients passed the full exams by two neurologists. 
None of examiners had any knowledge about the col-
league's diagnosis. Patients diagnosed as primary 
RLS by two neurologists were enrolled. The inclusion 
criteria were (i) Severity of symptoms at least to be 
moderate (point >10 based on IRLS) and (ii) Patients 
to be in primary RLS category. All patients under-
went routine laboratory exams too. After confirma-
tion, primary cases were enrolled. Eight patients were 
omitted during the study because of low compliance 
and insufficient data feedback and finally 60 patients 
passed the clinical trial successfully. All patients 
signed an informed consent and were informed for 
steps of clinical trial and the probable side effect of 
the drug. The trial was based on 3 periods of drug 
prescription (every period of the last one month) with 
one month wash out period. Only the designer of 
study was aware of the order of drug administration 
and the others (neurologists, drug administrators and 
patients) were blind to the pattern and order of drug 
administration. Table 2 shows the steps of trial. 
Placebo, 50 and 200 mg selenium were prescribed 
as capsules in equal shape and form. Patients and in-
vestigators did not know about the materials inside 
the capsules. The capsules were delivered to patients 
in three distinctive same packages with information 
insides, including start and end of the data. During the 
trial, all patients were questioned regularly about the 
consumption and dose effects of the medication and 
were encouraged to use the drugs precisely. After the 
end of each month of drug consumption, question-
naires were completed and asked them to describe the 
severity of the disease and any side effects of the 
drug. At least 10 declines in scale were considered as 
an appropriate response. All statistical analyses were 
performed using SPSS software (version 11.5, Chica-
go, IL, USA).The results were shown as mean±SD. In 
every period, before-after scores of males and females 
were analyzed separately by using nonparametric 
Wilcoxon test. Comparison of the effect of the drug 
in every period between males and females was as-
sessed by Mann-Whitney test. All before-after scores 
in the three groups were compared together by 
Freedman test. P-value of < 0.05 was considered as 
statistically significant. 
 
 
Results 
 
Sixty patients (34 females, mean age: 54±11.4 and 26 
males, mean age: 49±12.3) were enrolled. Table 3 
shows the rate of placebo and selenium efficacy. Rate 
of improvement (decline IRLS score>10) was signifi-
cantly higher in selenium than placebo group. Im-
provement rate between 50 and 200 mg of selenium 
consumption was not significantly different. 
 
 
Table 3: Score decline comparison between place-
bo and 50 and 200 µg of selenium. 
Score
decline 
Placebo
No. (%) 
50 µg sele-
nium  
No. (%) 
200 µg se-
lenium 
 No. (%) 
10-15  11 (18.3)  27 (45)  30 (50) 
15-20  0  4 (7)  6 (10) 
Total  11 (18.3)  31 (52)  36 (60) 
 
Patients score before and after treatment with pla-
cebo, 50 and 200 µg of selenium were shown in Table 
4. There were no significant differences between 
males and females in response to placebo, 50 and 200 
µg of selenium (p values respectively=0.489, 0.473 
and 0.446). Decline in score after treatment by 50 and 
200 µg of selenium was significantly higher than pla-
cebo group (Both p values were less than 0.001). Also 
difference between 50 and 200 µg of selenium was 
significant (p value=0.007). 
 
 
Discussion 
 
In our study, females were more afflicted by primary 
RLS than males (34 vs. 26).This may be due to sexual 
hormone effects, dietary regimen, psychologic and 
sleep problems in this gender. Also silent coincidence 
Table 2: Steps of trial 
State  Placebo  Washout  50 µg selenium Washout 200 µg selenium
Duration  One month  One month  One month  One month  One month Selenium in restless leg syndrome 
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disease in females may be more than males which we 
could not find them precisely. 
Table 5 shows the comparison between our study 
and other results, using RLS score for RLS respons-
es to treatment. According to Table 5, in most stud-
ies, the rate of score decline by placebo ranged be-
tween score of 5-8. The role of placebo was investi-
gated in declining score of RLS.
32 Increasing the 
opioid and dopaminergic system of brain may play 
an important role.
32 Maximal decrement in score was 
correlated to dopaminergic agonists (17.2 by trans-
dermal rotingtone), but the interesting fact was that 
despite the more declines in scores by dopminergics, 
loss of side effects by selenium consumption and 
safety use of selenium and score decline to 12.86, 
less compliance and more cost of dopaminergics, 
selenium may be more and well tolerated. Several 
studies implicate the role of selenium in reconstruc-
tion of the dopaminergic system.
23-25 Score declines 
by 50 and 200 µg of selenium were 12.86 and 14.03 
respectively and this difference was statistically sig-
nificant (p=0.007) but practically this difference was 
not cost effective. So we preferred to choose 50 µg 
of selenium for RLS treatment.  
Selenium in daily recommended dose of 50 µg de-
clines the score of RLS largely which may be due to 
improvement in the dopaminergic pathway (reverse 
thyrosine hydroxylase activity and prevention of the 
striatal dopamine depletion). Finally due to absence 
of side effects reported form selenium consumption, 
we can recommend selenium administration next to 
or instead of dopamine agonist for RLS symptoms 
improvement. 
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Table 4: Score comparison before and after treatment.
Score 
mean(SD)
a 
Placebo  50 µg 200 µg
Before After  P value Before After P value Before  After  P  
value 
Male 27.73 
(6.91) 
21.96 
(5.32) 
<0.001 26.32 
(5.34) 
13.50 
(4.24) 
<0.001 25.65 
(5.09) 
11.63 
(4.57) 
<0.001 
Female 29.21 
(6.34) 
22.87 
(5.71) 
<0.001 27.84 
(4.86)
14.95 
(4.52)
<0.001 27.23 
(4.91) 
13.19 
(3.82)
<0.001 
Total 28.57 
(5.82) 
22.48 
(4.32) 
<0.001 27.03 
(4.67) 
14.17 
(4.02) 
<0.001 25.89 
(5.44) 
11.86 
(4.62) 
<0.001 
a SD: Standard Deviation 
 
Table 5: Comparison of IRLS score decline between studies.
Study  Country  Year IRLS score decline  Price in Iran
(Consumption 
dose per day) 
Placebo Drug
Rahimdel   Iran  2010  6.09  12.86 
(Selenium) 
0.2 $
a 
Agarwal et al.
26 USA  2010  8.80  13.20 
(Gabapentine) 
1 $
a 
Hogl et al.
27 Austria  2010  _  17.20 
(Transdermal rotigo-
tine) 
N/A
b 
Walters et al.
28 USA  2004 8.70  11.20 
(Ropinirole) 
0.5 $
a 
Aizuwa et al.
29 Japan  2005 _  14.80 
(Cabergoline) 
4 $
a 
a $: US dollar 
b N/A: Not Available  Rahimdel et al. 
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